New DRUG APPROVALS ZELSUVMI™ (berdazimer sodium) Topical Gel Date of Approval: January 5, 2024 Company: Ligand Pharmaceuticals Treatment for: Molluscum Contagiosum Zelsuvmi (berdazimer sodium) is a nitric oxide-releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. WAINUA® (eplontersen) Injection Date of Approval: December 21, 2023 Company: Ionis Pharmaceuticals and AstraZeneca Treatment for: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) Wainua (eplontersen) is a transthyretin-directed antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. FILSUVEZ™ (birch triterpenes) Topical Gel - formerly Oleogel-S10 Date of Approval: December 19, 2023 Company: Chiesi Global Rare Diseases Treatment for: Epidermolysis Bullosa Filsuvez (birch triterpenes) is a topical birch bark extract indicated for the treatment of wounds associated with dystrophic epidermolysis bullosa and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older. iDOSE®TR (travoprost) Intracameral Implant Date of Approval: December 13, 2023 Company: Glaukos Corporation Treatment for: Glaucoma, Open Angle, Glaucoma/Intraocular Hypertension iDose TR (travoprost intracameral implant) is a long-duration prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). CASGEVY™ (exagamglogene autotemcel) Suspension for Intravenous Infusion Date of Approval: December 8, 2023 Company: Pharmaceuticals and CRISPR Therapeutics Treatment for: Sickle Cell Disease, Beta Thalassemia Casgevy (exagamglogene autotemcel) is a CRISPR/Cas9 genome-edited cell therapy for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News 5 A HENRY SCHEIN PUBLICATION BIOTHERAPEUTICS